“We’re advancing REC-3565, a potential best-in-class MALT1 inhibitor, to improve outcomes for patients with B-cell malignancies with limited treatment options,” said David Mauro, Chief Medical Officer ...
Professor Zeng Zexian's team from the Center for Quantitative Biology at the Peking University Academy for Advanced Interdisciplinary Studies, in collaboration with the Peking University-Tsinghua ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback